Trifluoroacetic acid → HCID 69542313, compound
Reaction equation
C(OC([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[N:22]([C:23]3[CH:28]=[CH:27][CH:26]=[CH:25][C:24]=3[Cl:29])[C:21]3[C:20](=[O:30])[N:19]([CH3:31])[C:18](=[O:32])[N:17]([CH2:33][C:34]([OH:36])=[O:35])[C:16]=3[N:15]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.[F:37][C:38]([F:43])([F:42])[C:39]([OH:41])=[O:40]>>[F:37][C:38]([F:43])([F:42])[C:39]([OH:41])=[O:40].[Cl:29][C:24]1[CH:25]=[CH:26][CH:27]=[CH:28][C:23]=1[N:22]1[C:21]2[C:20](=[O:30])[N:19]([CH3:31])[C:18](=[O:32])[N:17]([CH2:33][C:34]([OH:36])=[O:35])[C:16]=2[N:15]=[C:14]1[N:11]1[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]1Participants
3
Procedure
4-[7-(2-Chlorophenyl)-3-carboxymethyl-1-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl]piperazine-1-carboxylic acid tert-butyl ester (26 mg) was dissolved in trifluoroacetic acid, and was concentrated. The residue was purified by reversed phase high performance liquid chromatography to give 10.73 mg of the title compound.
Workup
- concentrationwas concentrated
- customThe residue was purified by reversed phase high performance liquid chromatography
Sources & evidence
- ORD record
- ord-4f6ded5d4a094ef798bf89f556b1e2b4
- Source dataset
- uspto-grants-2006_07
- Patent number
- US07074798B2
Reaction notes
Loading…